Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment;Adhärenz mit täglichen und wöchentlichen oralen bisphosphonaten in der osteoporosetherapie

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 22, 2006, Pages 1257-1262

  Bartl, R ^a   Gotte S ^b   Hadji, P ^c   Hammerschmidt, Thomas ^d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Facharzt fur Orthopadie   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d GLAXOSMITHKLINE   (Germany)

Author keywords

Adherence, persistence; Bisphosphonates; Compliance; Germany; Osteoporosis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRESCRIPTION; RISK FACTOR; UNSPECIFIED SIDE EFFECT; ADULT; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG SURVEILLANCE PROGRAM; FEMALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATIENT; PATIENT ATTITUDE; POSTMENOPAUSE OSTEOPOROSIS; RETROSPECTIVE STUDY; STATISTICS;

ADMINISTRATION, ORAL; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ALENDRONATE; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT COMPLIANCE; PATIENT DROPOUTS; RETROSPECTIVE STUDIES;

EID: 33746196684     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-946559     Document Type: Article

References (27)

1. Akesson K, Beusterien K, Hebborn A, Leidy NK, Simon J. Patient preference for once-monthly over once-weekly bisphosphonate treatment. Osteoporos Int 2004 (Suppl 3)16: 83
2. Caro JJ, Ishak KJ, Huybrechts KF et al. Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int 2003; 14 (Suppl 7): Abstract PL6
3. Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008
4. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310
5. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimes among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460
6. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav 2002; 3: 338-342
7. DVO (Dachverband Osteologie e.V.). DVO-Leitlinien zur Prophylaxe, Daignostik und Therapie der Osteoprose bei Frauen ab der Menopause, bei Männern ab dem 60. Lebensjahr (Fassung 2006, Entwurf), http://www. lutherhaus.de/osteo/leitlinien-dvo, letzter Zugriff: 20.01.2006,2006
8. Ettinger M, Gallagher R, Amonkar M et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum 2004; 15 (Suppl): 513
9. Finigan J, Bainbridge PR, Eastell R. Adherence to osteoporosis therapies. Osteoporos Int 2001; 12: 48-49
10. Giuffrida A, Torgerson DJ. Should we pay the patient? Review of financial incentives to enhance patient compliance. BMJ 1997; 315: 703-707
11. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003; 14: 259-262
12. Hughes DA. Economic impact of poor compliance with pharmaceuticals. Expert Rev Pharmacoeconomics Outcomes Research 2002; 2: 327-335
13. Kendler D, Kung AW, Fuleihan Gel H et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004; 48: 243-251
14. Lombas C, Hakim C, Zanchetta JR. Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 2001; 15: 529
15. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-49
16. Morris LS, Schulz RM. Medication compliance: the patient's perspective. Clin Ther 1993; 15: 593-606
17. van Penning-Beest FJA, Goettsch WG, Erkens JA, Herings RMC. Persistence with bisphosphonate therapy and the impact of dosing frequency in patients with post-menopausal osteoporosis. Value in Health 2004; 7: 724
18. Raue F, Scheld J, Schmitt S et al. Perception of osteoporosis in the German population. Calcif Tissue Int 2004; 74 (Suppl 1): 92-93
19. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther 1997; 19: 1446-1457
20. Sebaldt R, Shone L, Pham B et al. Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int 2004; 15 (Suppl 1): 107
21. Simon JA, Lewiecki EM, Smith ME et al. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a muticenter, randomized, open-label, cross-over study. Clin Ther 2002; 24: 1871-1886
22. Solomon DH, Avorn JA, Katz JN et al. Compliance with osteoporosis medications. Arch Intern Med 2005; 165: 2414-2419
23. Sung JC, Nichol MB, Venturini F et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998; 4: 1421-1430
24. Tosteson AN, Grove MR, Hammond CS et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003; 115: 209-216
25. WHO. Adherence to long-term therapies: evidence for action. In: editors. Adherence to long-term therapies: evidence for action. WHO/MNC/03.01; World Health Organization, 2003
26. Wogen J, Kreilick CA, Livornese RC et al. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting. J Manag Care Pharm 2003; 9: 424-429
27. Yood RA, Emani S, Reed JI et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965-968